IMvigor010: Primary analysis from a phase III randomized study of   adjuvant atezolizumab (atezo) versus observation (obs) in high-risk   muscle-invasive urothelial carcinoma (MIUC).

Document type:: Meeting Abstract
Author(s):: Hussain, Maha H. A.; Powles, Thomas; Albers, Peter; Castellano, Daniel; Daneshmand, Siamak; Gschwend, Juergen; Nishiyama, Hiroyuki; Oudard, Stephane; Tayama, Darren; Davarpanah, Nicole N.; Degaonkar, Viraj; Shi, Yi; Mariathasan, Sanjeev; Grivas, Petros; Peter, H. O.; Rosenberg, Jonathan E.; Geynisman, Daniel M.; Hoffman-Censits, Jean H.; Peter Petrylak, Daniel; Bellmunt, Joaquim
Title:: IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).
Journal title abbreviation:: J Clin Oncol
Year:: 2020
Journal volume:: 38 Suppl S
Journal issue:: 15
Print-ISSN:: 0732-183X
TUM Institution:: Urologische Klinik und Poliklinik
BibTeX

Occurrences: